PSILAdvisorShares Psychedelics ETF
Seeks long-term capital appreciation.
By AdvisorShares · Launched 2021
Annual Cost
1.00%
#5,196 of 5,861 · expensive
Fund Size
$41M
#3,827 of 5,861 · mid-size
Return (1Y)Goal
+57.2%
Track Record
4 years
#2,408 of 5,861 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$16,041+60.4%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundWhat it actually holds
By weightConcentration
Top 10 holdings = 66.4% of fundconcentrated
Relmada Therapeutics Inc.
10.2%
ATAIBECKLEY INC
9.9%
DEFINIUM THERAPEUTICS INC
8.5%
DREY INST PREF GOV MM-MDSVXX
7.9%
Compass Pathways plc
6.7%
Neurocrine Biosciences Inc
4.7%
Gh Research Plc
4.7%
Cybin Inc
4.6%
Alkermes PLC
4.6%
Johnson & Johnson
4.6%
Asset allocation
Stocks
96.0%
Bonds
4.0%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
40.7%High
Year-on-year price swings
Max drawdown
-92.7%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.38Below average
Sortino (3Y)
0.90Moderate downside risk
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks long-term capital appreciation.
- Strategy
- Actively manages investments in publicly listed life sciences companies focused on psychedelic medicines, including mid-, small-, and micro-cap companies in the U.S. and foreign markets. Concentrates at least 25% in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector.
- Inception date
- September 15, 2021
- Fund family
- AdvisorShares
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at PSIL. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04